1-12 of 12
Gordan Srkalovic
Close
Sort by
Journal Articles

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, Daisy Alapat, Adam Bagg, Joshua D Brandstadter, Mary Jo Lechowicz, Hongzhe Lee, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum
Journal: Blood
Blood (2022) 140 (Supplement 1): 6520–6521.
https://doi.org/10.1182/blood-2022-170102
Published: 2022
Journal Articles

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Sheila K Pierson, Mateo Sarmiento Bustamante, Joshua D Brandstadter, Daisy Alapat, Adam Bagg, Mary Jo Lechowicz, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum
Journal: Blood
Blood (2022) 140 (Supplement 1): 9378–9379.
https://doi.org/10.1182/blood-2022-170360
Published: 2022
Journal Articles

Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease

Sheila K Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S. Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S. Uldrick, Frits van Rhee, David C Fajgenbaum
Journal: Blood
Blood (2021) 138 (Supplement 1): 1623.
https://doi.org/10.1182/blood-2021-153397
Published: 2021
Journal Articles

Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease

Sheila K Pierson, Adam Bagg, Daisy Alapat, Megan S. Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S. Uldrick, Frits van Rhee, David C Fajgenbaum
Journal: Blood
Blood (2021) 138 (Supplement 1): 1622.
https://doi.org/10.1182/blood-2021-153840
Published: 2021
Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Sheila K Pierson, MS, Yue Ren, Johnson Khor, Eric Haljasmaa, Jasira Ziglar, Katherine Floess, Erin NaPier, Faizaan Akhter, Amy Y Liu, Damilola Gibson, Karan Kanhai, MD PhD, Rabecka Martin, PhD, Amy Chadburn, MD, Gordan Srkalovic, MD PhD, Megan S. Lim, MD PhD, Corey Casper, MD MPH, Thomas S. Uldrick, MD MS, Elaine S. Jaffe, MD, Frits van Rhee, MD PhD, Hongzhe Lee, PhD, David C Fajgenbaum, MDMBA,MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 1540.
https://doi.org/10.1182/blood-2019-131367
Published: 2019
Journal Articles

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Clinical Trials & Observations
Frits van Rhee, Peter Voorhees, Angela Dispenzieri, Alexander Fosså, Gordan Srkalovic, Makoto Ide, Nikhil Munshi, Stephen Schey, Matthew Streetly, Sheila K. Pierson, Helen L. Partridge, Sudipto Mukherjee, Dustin Shilling, Katie Stone, Amy Greenway, Jason Ruth, Mary Jo Lechowicz, Shanmuganathan Chandrakasan, Raj Jayanthan, Elaine S. Jaffe, Heather Leitch, Naveen Pemmaraju, Amy Chadburn, Megan S. Lim, Kojo S. Elenitoba-Johnson, Vera Krymskaya, Aaron Goodman, Christian Hoffmann, Pier Luigi Zinzani, Simone Ferrero, Louis Terriou, Yasuharu Sato, David Simpson, Raymond Wong, Jean-Francois Rossi, Sunita Nasta, Kazuyuki Yoshizaki, Razelle Kurzrock, Thomas S. Uldrick, Corey Casper, Eric Oksenhendler, David C. Fajgenbaum
Journal: Blood
Blood (2018) 132 (20): 2115–2124.
https://doi.org/10.1182/blood-2018-07-862334
Published: 2018
Includes: Supplemental data
Journal Articles

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

Clinical Trials & Observations
David C. Fajgenbaum, Thomas S. Uldrick, Adam Bagg, Dale Frank, David Wu, Gordan Srkalovic, David Simpson, Amy Y. Liu, David Menke, Shanmuganathan Chandrakasan, Mary Jo Lechowicz, Raymond S. M. Wong, Sheila Pierson, Michele Paessler, Jean-François Rossi, Makoto Ide, Jason Ruth, Michael Croglio, Alexander Suarez, Vera Krymskaya, Amy Chadburn, Gisele Colleoni, Sunita Nasta, Raj Jayanthan, Christopher S. Nabel, Corey Casper, Angela Dispenzieri, Alexander Fosså, Dermot Kelleher, Razelle Kurzrock, Peter Voorhees, Ahmet Dogan, Kazuyuki Yoshizaki, Frits van Rhee, Eric Oksenhendler, Elaine S. Jaffe, Kojo S. J. Elenitoba-Johnson, Megan S. Lim
Journal: Blood
Blood (2017) 129 (12): 1646–1657.
https://doi.org/10.1182/blood-2016-10-746933
Published: 2017
Journal Articles

Four Cycles of Standard Bortezomib and Dexamethasone Produce Significant Overall Response Rates In Patients with Relapsed/Refractory Multiple Myeloma

Harsha Trivedi, RN, PhD, Blanche Mavromatis, MD, Usha Sree Chamarthy, MD, Anas Al-Janadi, MD, Vicki Gilreath, RN, Gordan Srkalovic, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 5046.
https://doi.org/10.1182/blood.V116.21.5046.5046
Published: 2010
Journal Articles

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Aleksandr Lazaryan, MD, MPH, PhD, Rachid Baz, MD, Mohamad A Hussein, Jr, MD, Paul Elson, ScD, Beth Faiman, CNP, Becky Habecker, Mary Ann Karam, RN, Janice Reed, RN, Kimberly Hamilton, RN, Kellie Bruening, Gordan Srkalovic, MD, PhD, Steven Andresen, DO, Matt Kalaycio, MD, John William Sweetenham, MD, FRCP, Ronald Sobecks, MD, Robert Dean, MD, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Frederic J. Reu, MD
Journal: Blood
Blood (2010) 116 (21): 1967.
https://doi.org/10.1182/blood.V116.21.1967.1967
Published: 2010
Journal Articles

Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02).

Rafat Abonour, MD, Lijun A. Zhang, MD, Vincent Rajkumar, PhD, Gordan Srkalovic, MD, PhD, Philip R. Greipp, MD, Rafael Fonseca, MD, Morie Gertz, MD
Journal: Blood
Blood (2007) 110 (11): 3616.
https://doi.org/10.1182/blood.V110.11.3616.3616
Published: 2007
Journal Articles

Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.

Rony M. Abou-Jawde, MD, Janice Reed, RN, Megan Kelly, Luba Platt, BS, Mary Ann Karam, RN, Mary Ruth Kovak, MSN, MBA, Gordan Srkalovic, MD, PhD, Mohamad A. Hussein, MD
Journal: Blood
Blood (2004) 104 (11): 2419.
https://doi.org/10.1182/blood.V104.11.2419.2419
Published: 2004
Journal Articles

Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a Phase I/II Trial in Advanced Relapsed/Refractory Multiple Myeloma (RMM) Patients.

Mohamad A. Hussein, MD, Mary Ann Karam, RN, Catherine Brand, Greg L. Pearce, Janice Reed, RN, Kellie Bruening, Paul Sartori, Gordan Srkalovic, MD, PhD, Marta Olesnyckyj, RN, Robert Knight, MD, Kathe Balinski, RN, MA, Jerome Zeldis, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 208.
https://doi.org/10.1182/blood.V104.11.208.208
Published: 2004